title: Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules.
abstract: The aim of this study was to evaluate the ability of a low-fluence fractional erbium:yttrim-aluminum-garnet (Er:YAG) laser, with a wavelength of 2940 nm, for enhancing and controlling the skin permeation of imiquimod and macromolecules such as polypeptides and fluorescein isothiocyanate (FITC)-labeled dextran (FD). The in vitro permeation has been determined using a Franz diffusion cell, with porcine skin and nude mouse skin as the barriers. Hyperproliferative and ultraviolet (UV)-irradiated skins were also used as barrier models to mimic the clinical therapeutic conditions. Confocal laser scanning microscopy (CLSM) was used to examine the in vivo nude mouse skin uptake of peptide, FITC, and FD. Both in vitro and in vivo results indicated an improvement in permeant skin delivery by the laser. The laser fluence and number of passes were found to play important roles in controlling drug transport. Increases of 46- and 127-fold in imiquimod flux were detected using the respective fluences of 2 and 3 J/cm(2) with 4 pulses. An imiquimod concentration of 0.4% from aqueous vehicle with laser treatment was sufficient to approximate the flux from the commercial cream with an imiquimod dose of 5% without laser treatment, indicating a reduction of the drug dose by 125-fold. The enhancement of peptide permeation was size and sequence dependent, with the smaller molecular weight (MW) and more-hydrophilic entities showing greater enhancing effect. Skin permeation of FD with an MW of at least 150 kDa could be achieved with fractional laser irradiation. CLSM images revealed intense green fluorescence from the permeants after exposure of the skin to the laser. The follicular pathway was significant in laser-assisted permeation.
authors: Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei 110, Taiwan.
authors: Woan-Ruoh
authors: WR
authors: Lee
authors: Shing-Chuan
authors: SC
authors: Shen
authors: Saleh A
authors: SA
authors: Al-Suwayeh
authors: Hung-Hsu
authors: HH
authors: Yang
authors: Cheng-Yin
authors: CY
authors: Yuan
authors: Jia-You
authors: JY
authors: Fang
mesh_terms: D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D002851:Chromatography, High Pressure Liquid; D003911:Dextrans / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods*; D005260:Female; D000077271:Imiquimod; D066298:In Vitro Techniques; D053844:Lasers, Solid-State; D046911:Macromolecular Substances / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051379:Mice; D008819:Mice, Nude; D018613:Microscopy, Confocal; D010455:Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics; D012867:Skin / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects; D012869:Skin Absorption; D013552:Swine; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D000634:Aminoquinolines; D003911:Dextrans; D046911:Macromolecular Substances; D010455:Peptides; D000077271:Imiquimod